This is in line with the observation that, in triple-negative breast cancer patients, the presence of CD39+ T cells predicts an improved prognosis, and, in NSCLC, the redistribution of CD39+CD8+ T cells contributes to better clinical outcomes [79,80]. Here, ENTPD1 is linked to triple-negative breast carcinoma.